Is NVO a Danish stock or a US stock?

NVO is an American Depositary Receipt (ADR) listed on the NYSE. Each ADR represents one-third of a Novo Nordisk B share traded in Copenhagen. US investors buy NVO on the NYSE like any other US-listed stock.

How does the IRA drug pricing negotiation affect NVO?

The Inflation Reduction Act allows Medicare to negotiate prices for high-spend drugs. Ozempic and Wegovy have not been included in negotiation rounds as of early 2026, but the risk of future inclusion exists. If included, US net pricing for semaglutide products could face 10–25% reductions, directly impacting Novo Nordisk's largest market.

What happened in the CagriSema REDEFINE 1 trial?

The Phase 3 REDEFINE 1 trial for CagriSema (cagrilintide + semaglutide) reported results in December 2024 that came in below Wall Street's expectations for weight loss. NVO shares fell sharply following the readout. Follow-up REDEFINE 4 headline results were announced February 23, 2026, with detailed data expected at ADA in June 2026.

How does NVO compare to LLY in the GLP-1 market?

Eli Lilly's Zepbound (tirzepatide) demonstrated higher weight loss in clinical trials (~20–22%) vs Wegovy (~15–17%), driving market share gains for LLY. However, NVO retains global manufacturing scale, an established prescriber base, and Ozempic's strong position in type 2 diabetes. The competitive gap is real but not existential for Novo Nordisk.

What is amycretin and when could it reach the market?

Amycretin is Novo Nordisk's oral next-generation obesity candidate that targets both GLP-1 and amylin receptors. As of 2026, it is in Phase 2 clinical development. Assuming positive data, Phase 3 initiation and eventual FDA approval would likely take until the late 2020s at the earliest.

What are the key catalysts for NVO stock in 2026?

Key catalysts include: ADA 2026 investor event (June 7) with CagriSema detailed data, H1 2026 earnings (August 5), Capital Markets Day with long-term targets (September 21), and any updates on orforglipron (LLY's oral GLP-1) that could indicate competitive intensity.

Does NVO pay a dividend, and what is the yield?

Novo Nordisk does pay a semi-annual dividend. The ADR dividend reflects the underlying Danish krone dividend converted at prevailing exchange rates. Yield has historically been in the 1–2% range. US investors should note the 15% Danish withholding tax applies, which may be creditable against US tax liability.

What is the bear case that could push NVO below $60?

The bear case combines: IRA negotiation including Ozempic, LLY oral GLP-1 (orforglipron) capturing the convenience-driven market, CagriSema development discontinuation reducing pipeline value, and a strong USD reducing DKK-denominated earnings in dollar terms.

NVO Novo Nordisk Stock Outlook 2026: GLP-1 Dominance Unde...

Novo Nordisk created the GLP-1 obesity market as we know it. Ozempic became a cultural phenomenon, Wegovy redefined what weight loss medicine could achieve, and NVO shares tripled between 2021 and their 2024 peak. But after the December 2024 CagriSema REDEFINE 1 disappointment and Eli Lilly’s relentless market advances, Novo Nordisk enters 2026 as the incumbent defending territory rather than the disruptor seizing it.

This analysis reviews Q1 2026 financial results, the competitive landscape with LLY, the pipeline reality after the CagriSema setback, IRA pricing risk, and three scenario valuations. All financial figures cited reference the Q1 2026 earnings release (May 6, 2026) and StockAnalysis data.

Financial Snapshot: Q1 2026 Shows Resilience

Novo Nordisk reported Q1 2026 group revenue of approximately 96.8 billion DKK, a +24% year-over-year increase from ~78.1 billion DKK in Q1 2025. This figure follows FY2025 annual revenue of 309 billion DKK (+6.4% YoY), a sharp deceleration from the +25% and +31% growth rates of FY2024 and FY2023.

Period	Revenue (DKK)	YoY Growth
Q1 2026	~96.8B	+24%
FY2025	309.1B	+6.4%
FY2024	290.4B	+25.0%
FY2023	232.3B	+31.2%

The Q1 2026 rebound in quarterly growth rate (+24%) is encouraging relative to the FY2025 full-year figure and suggests that Wegovy volume growth may be accelerating again. However, investors must watch whether this pace is sustainable through H2 2026 or is partly a seasonal/inventory restocking effect.

The company’s Capital Markets Day (September 21, 2026) is the venue where management will update long-term revenue and margin targets — a critical event for resetting expectations.

The GLP-1 Franchise: What’s Still Working

Ozempic: The Underrated Workhorse

Ozempic (semaglutide 0.5mg/1mg/2mg weekly injection, type 2 diabetes) continues to generate the bulk of Novo Nordisk’s US revenue. Despite not being the obesity product, Ozempic benefits from: an enormous type 2 diabetes population, demonstrated cardiovascular outcome data (SELECT trial), and the halo effect of brand recognition. The cardiovascular indication, demonstrated in the SELECT trial, has expanded the label and prescribing rationale beyond glucose control.

Wegovy: Volume vs. Net Pricing Trade-Off

Wegovy (semaglutide 2.4mg weekly, obesity/overweight with comorbidities) is the flagship growth engine. US commercial access has expanded, but net pricing after rebates to pharmacy benefit managers remains a key variable. The Trump administration’s executive order pressure on drug pricing adds a layer of uncertainty beyond the IRA mechanism.

Outside the US, Wegovy is gaining coverage in key European markets, though reimbursement timelines vary significantly by country. Rybelsus (oral semaglutide, type 2 diabetes) provides a growing oral platform for the semaglutide franchise.

The CagriSema Problem: A Setback, Not a Collapse

What REDEFINE 1 Delivered

The Phase 3 REDEFINE 1 trial reported in December 2024 with weight loss results that fell short of Wall Street’s pre-announcement consensus estimates. The stock fell sharply on the readout — a pattern common when “the whisper number” significantly exceeds actual data. The trial was not a failure in absolute terms (the treatment showed meaningful weight reduction), but the delta versus analyst expectations was large enough to prompt a valuation reset.

Critical note: Specific percentage weight loss figures from REDEFINE 1 cited in secondary sources vary. I am not restating a specific number here because no primary Novo Nordisk press release with a final confirmed weight-loss figure was accessible for this article. Readers should verify the REDEFINE 1 data directly from the Novo Nordisk investor newsroom or the original publication.

REDEFINE 4 and the Path Forward

Headline results from REDEFINE 4 were released February 23, 2026. The detailed data presentation is scheduled for the ADA 2026 R&D Investor Event on June 7, 2026. That event will determine whether CagriSema’s regulatory path remains viable or whether Novo Nordisk pivots resources toward amycretin and other next-generation compounds.

Pipeline Beyond CagriSema

Amycretin: The Oral Prize

Amycretin, a single molecule targeting both GLP-1 receptors and amylin receptors in oral form, is Novo Nordisk’s most-watched early pipeline asset. Phase 1/2 data have shown promising weight reduction signals. If Phase 3 data replicate this, amycretin could challenge LLY’s orforglipron (also oral, GLP-1 only) for the massive unmet demand for a pill-form obesity treatment. Phase 3 initiation would likely come no earlier than 2026–2027; market launch would be late 2020s at the earliest.

Monlunabant: A Different Approach

Monlunabant is a CB1 receptor inverse agonist — a centrally-acting appetite suppressant with a different mechanism than GLP-1. Phase 2 studies are ongoing. The challenge: the CB1 class has a troubled regulatory history (rimonabant was withdrawn from European markets in 2008 due to psychiatric side effects). Novo Nordisk would need to demonstrate a clean neuropsychiatric safety profile in larger trials.

Competitive Landscape: The Lilly Gap Is Real

Attribute	NVO (Wegovy)	LLY (Zepbound)
Mechanism	GLP-1 mono	GLP-1/GIP dual
Clinical weight loss	~15–17%	~20–22%
US market positioning	Established, large Rx base	Fast-growing challenger
Oral pipeline	Amycretin (Phase 2)	Orforglipron (Phase 3)
US manufacturing	Expanding	Well-established
Cardiovascular label	SELECT trial (semaglutide)	SURMOUNT-4/SUMMIT data

Eli Lilly’s dual GLP-1/GIP mechanism (tirzepatide) has consistently shown numerically higher weight loss in head-to-head comparisons with GLP-1 monotherapy. This is the primary reason LLY now commands a valuation premium over NVO. See our LLY Eli Lilly stock outlook 2026 for the other side of this competition.

NVO’s counterargument centers on: global manufacturing capacity that LLY took longer to scale, Ozempic’s stronger type 2 diabetes position, and the potential that amycretin’s dual-receptor oral mechanism could differentiate from LLY’s orforglipron when data mature.

IRA and Pricing Risk: The Policy Overhang

The IRA’s Medicare drug price negotiation mechanism selects drugs based on high gross spend and time since FDA approval. As of Q1 2026, Ozempic and Wegovy have not been selected for negotiation — partly because the program has focused on older, longer-approved drugs in its early rounds, and partly due to political dynamics around GLP-1 drugs given their obesity healthcare cost-reduction potential.

However, the Trump administration’s separate executive order approach to drug pricing introduces a different, less predictable policy channel. Any executive action targeting GLP-1 pricing directly could affect NVO’s US revenue materially. This remains a risk to monitor quarterly, not a resolved issue.

For context, see our analysis of MRK Merck stock outlook 2026 and ABBV AbbVie stock outlook 2026, both of which face similar IRA exposure dynamics.

Three-Scenario Valuation

Bull Case ($90–$100): Pipeline Revival + Market Expansion

REDEFINE 4 + ADA 2026 data show CagriSema weight loss superiority versus Wegovy alone
Amycretin Phase 2 data positive, Phase 3 initiated
IRA negotiation risk deferred beyond 2027
Wegovy annual revenues approach $15B+ globally
NVO re-rates to 30–35x forward earnings

Base Case ($72–$80): Steady State, Modest Deceleration

Wegovy grows steadily, some share loss to Zepbound in higher-efficacy-seeking patients
CagriSema development continues but timeline extended to 2029+
IRA risk looms but is not crystallized
NVO trades at 24–27x forward earnings, a discount to LLY

Bear Case ($55–$65): Multiple Compression

REDEFINE ADA data disappoints; CagriSema development reconsidered
Orforglipron (LLY) launches successfully as oral pill, accelerating Wegovy share erosion
IRA/executive order action directly impacts Ozempic net pricing
USD strength reduces DKK earnings translation
NVO compresses to 18–22x forward earnings

These scenarios are analytical frameworks, not investment advice. NVO could trade outside all three ranges depending on factors not captured in this analysis.

Key Dates to Watch in 2026

Date	Event	Significance
June 7, 2026	ADA R&D Investor Event	CagriSema detailed REDEFINE data
August 5, 2026	H1 2026 Earnings	Wegovy/Ozempic H1 revenue trajectory
September 21, 2026	Capital Markets Day	Long-term revenue targets reset
November 4, 2026	Q1–Q3 2026 Earnings	Year-to-date performance

Bottom Line

NVO is not a broken story — it is a recalibration story. The GLP-1 market remains enormous and growing, Wegovy’s volume growth appears to be reaccelerating in Q1 2026, and Ozempic’s diabetes franchise is durable. What changed after REDEFINE 1 is the market’s willingness to pay a premium for the next-generation pipeline. That premium is on trial at ADA 2026.

For long-term investors comfortable with biotech volatility and policy risk, NVO at a discount to LLY represents a viable thesis. The ADA and Capital Markets Day events will be the decisive moments for whether 2026 is a recovery year or another reset.

Also consider reading: AMGN Amgen stock outlook 2026, BMY Bristol-Myers Squibb stock outlook 2026, JNJ Johnson & Johnson stock outlook 2026.

This article is for informational purposes only and does not constitute investment advice. Past performance and analyst estimates are not indicative of future results. All investment decisions carry risk.